Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The company is headquartered in Mississauga, Ontario. The company went IPO on 2014-09-24. The company is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The company is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Follow-Up Questions
Profound Medical Corp 'in CEO'su kimdir?
Dr. Arun Menawat 2015 'den beri şirketle birlikte olan Profound Medical Corp 'in Chairman of the Board 'ıdır.
PROF hissesinin fiyat performansı nasıl?
PROF 'in mevcut fiyatı $4.41 'dir, son işlem günde 6.9% increased etti.
Profound Medical Corp için ana iş temaları veya sektörler nelerdir?
Profound Medical Corp Health Care endüstrisine ait ve sektör Health Care 'dir
Profound Medical Corp 'in piyasa değerlemesi nedir?
Profound Medical Corp 'in mevcut piyasa değerlemesi $132.6M 'dir
Profound Medical Corp al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Profound Medical Corp için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 4 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
